- Trial phase
- Phase 1
- Time to market
- Not applicable; development has been paused with no timeline for resumption.
- Why 2/10
- ABCL575 has been shelved (development paused) per AbCellera's Q3 2026 earnings call on November 9, 2026. With no active clinical trial or upcoming hard-dated catalyst, the impact score is low.
AbCellera announced on its Q3 2026 earnings call (November 9, 2026) that it is shelving further development of ABCL575 for now, while prioritizing ABCL635 (hot flash treatment) for late-stage development. Investors should watch whether AbCellera ever resumes ABCL575 development or partners it out, but near-term attention is on ABCL635's Phase 2-to-Phase 3 transition in 2027.
Price Chart
Executive Summary
ABCL575 is an anti-OX40L monoclonal antibody that AbCellera was developing for moderate-to-severe atopic dermatitis. It showed promising preclinical data and entered Phase 1 clinical trials in Canada in mid-2025. However, on November 9, 2026, AbCellera announced it is shelving further development of ABCL575 to focus resources on its lead asset ABCL635 (a hot flash treatment), which recently reported positive Phase 2 results. With no active development or upcoming catalysts, ABCL575 is currently a parked program.
How It Works
ABCL575 is an antibody designed to block OX40L, a protein involved in activating immune cells that drive inflammation. By blocking OX40L, the drug aims to reduce the inflammatory response underlying atopic dermatitis (eczema). It is engineered to last longer in the body (half-life extended) and to avoid triggering unwanted immune cell activity (Fc-silenced).
Trial Status
ABCL575 completed first-in-human dosing in a Phase 1 trial (started Q3 2025, first participants dosed August 2025). However, per AbCellera's Q3 2026 earnings call on November 9, 2026, the company has shelved further development of this antibody candidate for now, prioritizing its other pipeline asset ABCL635 instead.
The Two-Sided Case
Upcoming Catalysts
- No upcoming catalysts: ABCL575 development has been shelved per the Q3 2026 earnings call.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbCellera Biologics Inc. 8-K ABCL ·Originating report